miércoles, 3 de junio de 2015

Cancer: Un "cancer" para la economia de los sitemas de salud.

The most daunting challenge facing the approved drugs—not to mention hundreds of pipeline agents targeting other inhibitory pathways, plus upcoming disparate but equally promising modalities, like vaccines—is monetary. Even before new immunotherapies arrived, oncology was undergoing breathtaking growth. Between 2003 and 2013, global spending on cancer doubled. Expenditures on oncology medicines grew by 10% in 2014, reaching $100 billion, up from $75 billion just five years earlier. 

More sobering, growth has thus far been driven by targeted therapies, drugs like Novartis’s Gleevec. The industry has not yet begun to feel the full impact of immunotherapy, where a CTLA-4 combined with Opdivo retails for $270,000 annually—price tags that promise to redefine the word “unsustainable.” 

On their own, anti-PD1 therapies Keytruda and Opdivo sell for around $150,000 a year. 
Another recent example includes Pfizer’s Ibrance (palbociclib), approved in February 2015 and priced at about $120,000 a year.

 Ver también:

120 expertos mundiales alertan del precio de terapias contra cancer.

Publicar un comentario